---
title: "Beijing Chunlizhengda Forecasts Profit to Nearly Double in 2025 on Procurement and Overseas Growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274138949.md"
description: "Beijing Chunlizhengda Medical Instruments Co., Ltd. (HK:1858) forecasts a significant increase in profitability for 2025, expecting net profit attributable to shareholders to rise by 96% to 130%, reaching RMB244.99 million to RMB287.99 million. The growth is attributed to centralized procurement inclusion, international expansion, and improved operational management. The latest analyst rating for the stock is a Buy, with a price target of HK$18.50. The company specializes in orthopedic medical instruments and is expanding its international presence."
datetime: "2026-01-29T11:10:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274138949.md)
  - [en](https://longbridge.com/en/news/274138949.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274138949.md)
---

# Beijing Chunlizhengda Forecasts Profit to Nearly Double in 2025 on Procurement and Overseas Growth

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An announcement from Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H ( (HK:1858) ) is now available.

Beijing Chunlizhengda Medical Instruments Co., Ltd. expects a sharp jump in profitability for 2025, forecasting net profit attributable to shareholders of RMB244.99 million to RMB287.99 million, up about 96% to 130% year on year, and net profit excluding non-recurring items of RMB229.54 million to RMB269.54 million, up roughly 143% to 185%. The company attributes the projected surge in earnings to the growth potential released after its product lines were included in centralized procurement, steady progress in its international expansion, and improvements in operational management and resource allocation, which have supported sustained revenue growth and higher overall profitability, although the figures remain preliminary and unaudited.

The most recent analyst rating on (HK:1858) stock is a Buy with a HK$18.50 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.

**More about Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H**

Beijing Chunlizhengda Medical Instruments Co., Ltd. is a PRC-incorporated medical device manufacturer listed in Hong Kong, focusing on orthopedic and related medical instruments. The group operates both domestically and internationally, with product lines that participate in China’s centralized procurement system and an expanding overseas business footprint as part of its internationalization strategy.

**Average Trading Volume:** 1,530,855

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$9.76B

Learn more about 1858 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [01858.HK](https://longbridge.com/en/quote/01858.HK.md)

## Related News & Research

- [Chunlizhengda Seeks Mandate for Up to 10% H-Share Buyback](https://longbridge.com/en/news/284665850.md)
- [Explained: What are bond yields and why markets watch them closely?](https://longbridge.com/en/news/287168006.md)
- [Comey eyes new 'anti-weaponization' fund: 'I'm guessing I'll be in line'](https://longbridge.com/en/news/286948735.md)
- [Scott Jennings voices concern over Trump's $1.7B DOJ fund](https://longbridge.com/en/news/286922300.md)
- [Trump faces record-low approval on inflation as retirees struggle](https://longbridge.com/en/news/286834439.md)